Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: Efficacy and safety outcomes of a randomized, multi-center phase II study investigating-Reference-Cited by-同舟云学术

Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: Efficacy and safety outcomes of a randomized, multi-center phase II study investigating

Published:2014-01 Issue:1 Volume:110 Page:126-131
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

van den Heuvel Michel M.,Uyterlinde Wilma,Vincent Andrew D.,de Jong Jeroen,Aerts Joachim,Koppe Frederike,Knegjens Joost,Codrington Henk,Kunst Peter W.E.,Dieleman Edith,Verheij Marcel,Belderbos José

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology

Reference36 articles.

1. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer;Auperin;J Clin Oncol,2010

2. Concurrent chemoradiotherapy in non-small cell lung cancer;O’Rourke;Cochrane Database Syst Rev,2010

3. Chemoradiation therapy in nonsmall cell lung cancer;Baas;Curr Opin Oncol,2011

4. Accelerated high-dose radiotherapy alone or combined with either concomitant or sequential chemotherapy; treatments of choice in patients with Non-Small Cell Lung Cancer;Uitterhoeve;Radiat Oncol,2007

5. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973);Belderbos;Eur J Cancer,2007

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non–Small-Cell Lung Cancer;Clinical Lung Cancer;2023-11

2. Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis;Future Oncology;2022-09

3. Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer—results from a retrospective analysis;Interactive CardioVascular and Thoracic Surgery;2021-11-04

4. Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges;Future Oncology;2021-10

5. Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents;Translational Lung Cancer Research;2021-04